NATCO Pharma has informed that it enclosed the Press Release under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the receipt of Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) Inspection at our Visakhapatnam, Andhra Pradesh, Finished Dosage Formulations (FDF) Unit.